← Leaderboards
Mien-Chie Hung
University Of Texas Md Anderson Can Ctr
$10,660,923
Attributed
$11,343,461
Total exposure
15
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–19$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$22,946,744 · 16
By mechanism
P01$14,635,965 · 3
R01$5,351,430 · 5
P50$1,235,824 · 3
U01$1,004,522 · 1
T32$441,605 · 1
P30$262,398 · 2
Top collaborators
- Dmitri Lapotko2 shared
- Vladimir P Torchilin2 shared
- Gunter Blobel1 shared
- Edward B Leof1 shared
- Lynn M Matrisian1 shared
- Marit Nilsen-Hamilton1 shared
- Christopher Mark Overall1 shared
- Joann Trejo1 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- David G. Johnson$18,592,669
- Zahid H Siddik$6,100,049
- Menashe Bareli$6,643,202
- K Kian Ang$2,378,003
- Andrew P Feinberg$58,785,687
Others in their field
Top investigators on “Malignant Breast Neoplasm”
- David Heimbrook · Leidos Biomedical Research, Inc.$347,312,063
- Norman Wolmark · Nsabp Foundation, Inc.$122,067,540
- Walter John Curran · Thomas Jefferson University$97,002,422
- Monica M Bertagnolli · Strang Cancer Prevention Center$84,975,759
- Joseph P. Costantino · University Of Pittsburgh At Pittsburgh$68,847,428
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$60,763,376
Research focus
Malignant Breast NeoplasmTumor ProgressionFundingCancer CellMolecularMalignant NeoplasmsBasePlayReportingMammary NeoplasmsMediatingGrowth Factor ReceptorsCellsPathway InteractionsProgress ReportsSignal TransductionRegulationTumorEpidermal Growth Factor ReceptorGene ExpressionBreast Cancer CellComplexGene TherapyNeoplasm /Cancer Genetics
Grant awards (59)
14 Functional Genomics Core$232,779
P30 · FY2019 · CA · contact PI
26 Cancer Biology and Metastasis$18,707
P30 · FY2019 · CA · contact PI
26 Cancer Biology and Metastasis$5,456
P30 · FY2019 · CA · contact PI
14 Functional Genomics Core$5,456
P30 · FY2019 · CA · contact PI
Negative regulation of C-type lectin receptor signaling in response to fungal infection$400,000
R01 · FY2018 · AI · contact PI
Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance$464,964
U01 · FY2017 · CA
Rational Combination Therapy with PARP Inhibitors in Triple Negative Breast Cancer$425,403
R01 · FY2017 · CA · contact PI
Negative regulation of C-type lectin receptor signaling in response to fungal infection$400,000
R01 · FY2017 · AI · contact PI
Training Grant in Cancer Biology$223,492
T32 · FY2017 · CA · contact PI
Mechanical Drugs: Harnessing Cancer Aggressiveness to Overcome Its Resistance$539,558
U01 · FY2016 · CA
Training Grant in Cancer Biology$218,113
T32 · FY2016 · CA · contact PI
Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation$1,106,159
P01 · FY2014 · CA · contact PI
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer Pro$501,837
P01 · FY2014 · CA · contact PI
Tumor Progression of Nuclear EGFR in Breast Cancer$290,101
R01 · FY2014 · CA · contact PI
Administrative Core$87,852
P01 · FY2014 · CA · contact PI
Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation$1,071,956
P01 · FY2013 · CA · contact PI
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer Pro$486,323
P01 · FY2013 · CA · contact PI
Tumor Progression of Nuclear EGFR in Breast Cancer$281,129
R01 · FY2013 · CA · contact PI
Administrative Core$85,123
P01 · FY2013 · CA · contact PI
Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation$1,140,375
P01 · FY2012 · CA · contact PI
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer Pro$517,358
P01 · FY2012 · CA · contact PI
Tumor Progression of Nuclear EGFR in Breast Cancer$299,073
R01 · FY2012 · CA · contact PI
Administrative Core$90,571
P01 · FY2012 · CA · contact PI
Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation$1,140,952
P01 · FY2011 · CA · contact PI
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer Pro$517,935
P01 · FY2011 · CA · contact PI
Tumor Progression of Nuclear EGFR in Breast Cancer$299,073
R01 · FY2011 · CA · contact PI
Administrative Core$90,572
P01 · FY2011 · CA · contact PI
Growth Factor Receptor in Breast Cancer Progression and Metabolic Regulation$1,204,022
P01 · FY2010 · CA · contact PI
Tyrosine Kinase-Dependant and - Independent Pathways of EGFR in Breast Cancer Pro$561,739
P01 · FY2010 · CA · contact PI
Tumor Progression of Nuclear EGFR in Breast Cancer$308,322
R01 · FY2010 · CA · contact PI
Administrative Core$93,372
P01 · FY2010 · CA · contact PI
Targeting Breast Cancer Specific Gene Therapy$309,634
P50 · FY2009 · CA · contact PI
Development of E1A Gene Therapy in Ovarian Cancer$211,121
P50 · FY2009 · CA · contact PI
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$151,419
P01 · FY2009 · CA · contact PI
HER2 in Breast Tumor Progression and Metastasis$293,511
R01 · FY2008 · CA · contact PI
Targeting Breast Cancer Specific Gene Therapy$208,449
P50 · FY2008 · CA · contact PI
Development of E1A Gene Therapy in Ovarian Cancer$147,397
P50 · FY2008 · CA · contact PI
Symposium on Extracellular and Membrane Proteases in Cell Signaling$15,000
R13 · FY2008 · CA
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$1,131,894
P01 · FY2007 · CA · contact PI
HER2 in Breast Tumor Progression and Metastasis$293,511
R01 · FY2007 · CA · contact PI
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$1,140,441
P01 · FY2006 · CA · contact PI
HER2 in Breast Tumor Progression and Metastasis$302,276
R01 · FY2006 · CA · contact PI
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$52,404
P01 · FY2006 · CA · contact PI
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$1,142,273
P01 · FY2005 · CA
HER2 in Breast Tumor Progression and Metastasis$309,550
R01 · FY2005 · CA
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$51,054
P01 · FY2005 · CA
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$1,115,022
P01 · FY2004 · CA
HER2 in Breast Tumor Progression and Metastasis$309,550
R01 · FY2004 · CA
E1A GENE THERAPY IN BREAST CANCER$236,952
R01 · FY2004 · CA
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$49,742
P01 · FY2004 · CA
GROWTH FACTOR RECEPTOR SIGNALING IN BREAST CANCER$1,105,570
P01 · FY2003 · CA
E1A GENE THERAPY IN BREAST CANCER$230,051
R01 · FY2003 · CA
E1A GENE THERAPY IN BREAST CANCER$223,350
R01 · FY2002 · CA
E1A gene therapy in ovarian cancer$0
P50 · FY2002 · CA
E1A gene therapy in ovarian cancer$0
P50 · FY2002 · CA
E1A GENE THERAPY IN BREAST CANCER$224,448
R01 · FY2001 · CA
E1A gene therapy in ovarian cancer$0
P50 · FY2001 · CA
E1A gene therapy in ovarian cancer$359,223
P50 · FY2000 · CA
PEA 3 IN HER 2/NEU OVEREXPRESSING OVARIAN CANCER$225,130
R01 · FY2000 · CA